Italy · biotech/health
Italy · biotech/healthErydel
Erydel develops technology for drug delivery of pharmacological agents through red blood cells.
PrivateFor profit
Against its peers
Set against 621 biotech/health companies worldwide. The ring marks the typical peer.
Across all 5.9M companies: larger than 33% of those with a size listed; older than 40% of those with a founding year.
About Erydel
BiotechnologyHealth CarePharmaceutical
Funding, as listed
What the source datasets report. We have not watched these rounds ourselves.
$44M
raised in total, currency not stated across 3 rounds
Last raised Apr 2018, 8 years ago
- Rounds
- 3
- Latest round
- Series b
- Investors
- 52 leading
Key facts
Who started it and how it trades.
- Founded by
- Mauro Magnani
Every detail we hold
Everything the source datasets list about Erydel, field by field. Contact details are held but never shown.
The company7 fields
- Name
- Erydel
- Type
- For profit
- Status
- Private
- Founded
- 2007
- Founders
- Mauro Magnani
- Industry
- biotech/health
- Categories
- Biotechnology, Health Care, Pharmaceutical
Where2 fields
- Country
- Italy
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach1 field
- Staff band
- 11-50
Show 9 more fieldsShow fewer fields
Funding, as listed7 fields
- Total
- 44,000,000 (currency not stated)
- Rounds
- 3
- Latest round
- Series b
- Latest round date
- Apr 2018
- Investors
- 5
- Lead investors
- 2
- Listing status
- private
About this record2 fields
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Erydel may be growing as it has been successfully acquired by Quince Therapeutics, which is a significant corporate development indicating a strategic expansion. The acquisition by a larger entity often suggests positive valuation and potential for scaling operations. Furthermore, Erydel is listed among key companies in a clinical pipeline research report, which implies active involvement in the biotechnology and pharmaceutical industry. The mention in the context of a clinical pipeline also suggests ongoing research and development activities, which are critical for growth in the health care sector.
Companies like Erydel
biotech/health in Italy.
Build a lead list
Every biotech/health company, filtered by size, age and reach, ready to export with emails on Pro.